Go Pro

Healthcare Stocks List

This page shows information about the 50 largest healthcare sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck & Co., Inc..

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,262.94 -17.40 (-1.36%)
As of 01:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company recently reported earnings per share (EPS) of $8.38, significantly exceeding analyst expectations, indicating strong financial performance and potential for future growth.
  • Eli Lilly and Co has a robust net margin of over 33%, suggesting efficient management and profitability, which can lead to higher returns for investors.
  • The current stock price is around $1,376, reflecting positive market sentiment and investor confidence in the company's future prospects.

Cons of Eli Lilly and Company

  • The dividend yield is relatively low at 0.6%, which may not attract income-focused investors looking for higher returns from dividends.
  • Recent insider selling, including significant transactions by executives, could raise concerns about the company's future performance and insider confidence.
  • Despite strong earnings, the stock price has seen fluctuations, which may indicate volatility and risk for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.19 trillion
P/E Ratio
42.38
Consensus Rating
Moderate Buy
Consensus Price Target
$1,292.18 (+2.3% Upside)
Volume
1.05 million shares
Average Volume
3.10 million shares
Today's Range
$1,257.00
$1,280.28
50-Day Range
$1,098.78
$1,280.62
52-Week Range
$694.23
$1,292.65
Dividend Yield
0.56%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$270.23 -3.18 (-1.16%)
As of 01:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $250, which is significantly lower than its fifty-two week high of $274.90, potentially offering a buying opportunity for investors.
  • Johnson & Johnson reported a strong quarterly revenue of $25.31 billion, exceeding analyst estimates, indicating robust business performance.
  • The company has a solid return on equity of 32.42%, reflecting effective management and profitability, which can be attractive to investors looking for strong financial health.

Cons of Johnson & Johnson

  • The stock has a relatively high P/E ratio of 30.42, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Johnson & Johnson's beta of 0.24 suggests lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
  • Despite recent revenue growth, the company faces ongoing challenges in the healthcare sector, which could impact future performance and investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$651.23 billion
P/E Ratio
31.31
Consensus Rating
Moderate Buy
Consensus Price Target
$268.22 (-0.7% Downside)
Volume
2.33 million shares
Average Volume
8.25 million shares
Today's Range
$269.86
$273.40
50-Day Range
$228.37
$273.19
52-Week Range
$173.33
$276.47
Dividend Yield
1.98%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$264.75 -1.22 (-0.46%)
As of 01:58 PM Eastern

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has recently received a positive recommendation for the reimbursement of UBRELVY in Canada, which could enhance its growth potential in the neuroscience market.
  • The company reported strong sales from its immunology products, Skyrizi and Rinvoq, contributing significantly to its recent quarterly growth and exceeding earnings expectations.
  • AbbVie’s stock is currently priced around $274, which is close to the average target price set by analysts, indicating potential for further appreciation.

Cons of AbbVie

  • The recent acquisition of Apogee Therapeutics has increased AbbVie's debt significantly, which may raise concerns about financial leverage and risk for dividend-focused investors.
  • Despite positive developments, some analysts have indicated limited near-term upside potential for the stock, suggesting that it may be slightly overvalued at current levels.
  • AbbVie’s high price-to-earnings ratio indicates that the stock may be expensive relative to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$467.76 billion
P/E Ratio
74.79
Consensus Rating
Moderate Buy
Consensus Price Target
$275.95 (+4.2% Upside)
Volume
2.53 million shares
Average Volume
6.85 million shares
Today's Range
$262.72
$265.93
50-Day Range
$216.63
$265.63
52-Week Range
$190.75
$267.47
Dividend Yield
2.76%
Merck & Co., Inc. stock logo

4. Merck & Co., Inc. NYSE:MRK

$151.89 -0.31 (-0.20%)
As of 01:58 PM Eastern

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has recently raised its FY 2026 earnings guidance, indicating strong future performance potential with an EPS range of 2.660-2.760.
  • The company has a robust portfolio, including the latest cancer immunotherapy, Keytruda, which continues to receive positive trial results and approvals, enhancing its market position.
  • Merck's current stock price is around $138, reflecting a strong market presence and investor confidence, supported by a consensus rating of "Moderate Buy" from analysts.

Cons of Merck & Co., Inc.

  • Merck's dividend payout ratio is currently at 272.00%, which may raise concerns about sustainability, as it indicates that the company is paying out more in dividends than it earns.
  • Despite positive developments, the stock has seen significant insider selling, with executives offloading over 86,000 shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • The net margin of 4.77% suggests that while revenue is growing, profitability may be under pressure, which could impact future earnings and investor returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$374.74 billion
P/E Ratio
121.51
Consensus Rating
Moderate Buy
Consensus Price Target
$142.10 (-6.4% Downside)
Volume
8.78 million shares
Average Volume
10.78 million shares
Today's Range
$148.52
$152.52
50-Day Range
$114.04
$152.21
52-Week Range
$77.58
$153.50
Dividend Yield
2.52%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$385.67 -2.94 (-0.76%)
As of 01:59 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company has demonstrated a solid return on equity, indicating effective management and profitability relative to shareholder equity.
  • UnitedHealth Group recently announced a quarterly dividend of $2.32, translating to an annualized dividend of $9.28, which offers a dividend yield of approximately 2.3%. This can provide a steady income stream for investors.
  • With a net margin of 3.14%, the company shows a healthy profit after expenses, which is a positive indicator of financial health.

Cons of UnitedHealth Group

  • The company's net margin of 3.14% may indicate that there is limited room for profit growth, which could affect long-term returns.
  • Despite a slight revenue increase of 0.4% compared to the same quarter last year, this growth rate may not be sufficient to attract aggressive investors looking for high-growth opportunities.
  • The dividend payout ratio is currently at 59.72%, which means a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth initiatives.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$346.17 billion
P/E Ratio
24.82
Consensus Rating
Moderate Buy
Consensus Price Target
$455.92 (+18.2% Upside)
Volume
2.17 million shares
Average Volume
7.87 million shares
Today's Range
$385.26
$392.71
50-Day Range
$388.03
$436.19
52-Week Range
$255.96
$461.62
Dividend Yield
2.36%
Novartis stock logo

6. Novartis NYSE:NVS

$157.44 -2.87 (-1.79%)
As of 01:59 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG has demonstrated strong financial performance with a return on equity of over 38%, indicating effective management and profitability.
  • The company boasts a robust net margin of approximately 23%, suggesting that it retains a significant portion of revenue as profit, which is attractive for investors seeking stable returns.
  • With a current stock price around $152, Novartis AG is positioned within a favorable range, making it an appealing option for potential investors looking for growth opportunities.

Cons of Novartis

  • Despite its strong financials, Novartis AG has a relatively high price-to-earnings ratio of around 23.90, which may indicate that the stock is overvalued compared to its earnings.
  • The company has a debt-to-equity ratio of 0.89, suggesting a moderate level of debt that could pose risks if not managed properly, especially in fluctuating market conditions.
  • Novartis AG's current ratio of 0.86 indicates that it may face challenges in meeting short-term liabilities, which could affect liquidity and operational flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$300.42 billion
P/E Ratio
23.75
Consensus Rating
Hold
Consensus Price Target
$141.20 (-10.3% Downside)
Volume
737,046 shares
Average Volume
1.95 million shares
Today's Range
$156.81
$159.33
50-Day Range
$147.17
$160.39
52-Week Range
$121.57
$170.46
Dividend Yield
1.99%
Astrazeneca stock logo

7. Astrazeneca NYSE:AZN

$165.44 +0.49 (+0.30%)
As of 01:59 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$256.58 billion
P/E Ratio
24.73
Consensus Rating
Moderate Buy
Consensus Price Target
$211.00 (+27.5% Upside)
Volume
3.31 million shares
Average Volume
2.76 million shares
Today's Range
$161.48
$165.57
50-Day Range
$155.79
$194.96
52-Week Range
$145.79
$212.71
Dividend Yield
2.71%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$434.71 -7.65 (-1.73%)
As of 01:58 PM Eastern

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $372, which reflects a strong performance in the biotechnology sector.
  • Amgen Inc. reported impressive quarterly earnings, with earnings per share surpassing analysts' expectations, indicating robust financial health.
  • The company has a solid revenue growth of 9.5% year-over-year, showcasing its ability to expand and generate income.

Cons of Amgen

  • The company has a high debt-to-equity ratio of 4.44, indicating significant leverage which could pose risks in economic downturns.
  • Amgen Inc. has a price-to-earnings-growth ratio of 3.86, suggesting that the stock may be overvalued relative to its growth rate.
  • Despite strong earnings, the stock has received mixed ratings from analysts, with a consensus rating of "Hold," indicating uncertainty in future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$235.02 billion
P/E Ratio
27.02
Consensus Rating
Hold
Consensus Price Target
$380.43 (-12.5% Downside)
Volume
1.05 million shares
Average Volume
2.72 million shares
Today's Range
$431.46
$441.34
50-Day Range
$337.60
$442.36
52-Week Range
$269.77
$443.20
Dividend Yield
2.40%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$629.16 +15.62 (+2.55%)
As of 01:58 PM Eastern

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company has demonstrated strong financial performance, with quarterly revenue increasing by over 10% year-over-year, indicating robust demand for its products and services.
  • Thermo Fisher Scientific Inc. has set its fiscal year 2026 earnings per share (EPS) guidance between 24.930 and 25.330, suggesting confidence in continued profitability and growth.
  • The current stock price is around $574, which may present a favorable entry point for investors looking to capitalize on potential future growth.

Cons of Thermo Fisher Scientific

  • Insider selling has been notable, with significant shares sold by executives, which could raise concerns about their confidence in the company's future performance.
  • The dividend payout ratio is currently at 10.11%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Analysts have varied opinions on the stock, with some price targets being significantly lower than the current stock price, indicating potential volatility and uncertainty in market sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$232.63 billion
P/E Ratio
33.84
Consensus Rating
Moderate Buy
Consensus Price Target
$619.41 (-1.5% Downside)
Volume
1.45 million shares
Average Volume
2.28 million shares
Today's Range
$607.37
$634.70
50-Day Range
$460.62
$614.32
52-Week Range
$435.27
$643.99
Dividend Yield
0.32%
Novo Nordisk A/S stock logo

10. Novo Nordisk A/S NYSE:NVO

$46.31 -0.17 (-0.37%)
As of 01:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $46, which is significantly lower than its twelve-month high, indicating potential for growth.
  • With a market capitalization of approximately $198.60 billion, Novo Nordisk is a major player in the pharmaceutical industry, providing stability and growth potential.
  • The company reported a strong net margin of over 35%, suggesting efficient management and profitability, which can lead to higher returns for investors.

Cons of Novo Nordisk A/S

  • The price-to-earnings (P/E) ratio is around 10.88, which, while not excessively high, may indicate that the stock is fairly valued, limiting upside potential.
  • The company has a debt-to-equity ratio of 0.59, which, while manageable, suggests that it is not entirely debt-free, potentially posing risks in economic downturns.
  • Recent reports indicate that some analysts have issued "hold" ratings, suggesting that there may not be strong bullish sentiment in the market currently.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$206.77 billion
P/E Ratio
11.32
Consensus Rating
Hold
Consensus Price Target
$64.94 (+40.2% Upside)
Volume
4.89 million shares
Average Volume
17.83 million shares
Today's Range
$46.18
$46.90
50-Day Range
$43.20
$51.56
52-Week Range
$35.12
$64.16
Dividend Yield
1.78%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$114.64 +0.21 (+0.18%)
As of 01:58 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $98, which is significantly lower than its twelve-month high, suggesting potential for growth.
  • Abbott Laboratories reported a strong quarterly earnings performance, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $191.52 billion, reflecting its stability and prominence in the healthcare sector.

Cons of Abbott Laboratories

  • The company's payout ratio is currently at 81.55%, which may indicate that a large portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
  • Abbott Laboratories has a quick ratio of 0.97, suggesting that it may face challenges in meeting short-term liabilities without selling inventory, which could be a concern for liquidity.
  • The firm has a relatively high P/E ratio of 35.82, which may suggest that the stock is overvalued compared to its earnings, making it a riskier investment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$198.37 billion
P/E Ratio
37.10
Consensus Rating
Moderate Buy
Consensus Price Target
$118.67 (+3.5% Upside)
Volume
2.30 million shares
Average Volume
11.88 million shares
Today's Range
$113.99
$115.23
50-Day Range
$87.78
$114.50
52-Week Range
$81.97
$137.49
Dividend Yield
2.24%
Gilead Sciences stock logo

12. Gilead Sciences NASDAQ:GILD

$145.22 -2.38 (-1.61%)
As of 01:58 PM Eastern

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company reported a strong quarterly earnings per share (EPS) of $2.03, exceeding analysts' expectations, which indicates robust financial performance and potential for future growth.
  • Gilead Sciences, Inc. achieved a revenue of $6.96 billion for the quarter, surpassing analyst estimates, showcasing its ability to generate significant income.
  • With a return on equity of 48.19%, Gilead demonstrates effective management of shareholder equity, which is a positive indicator for investors looking for efficient capital use.

Cons of Gilead Sciences

  • Despite recent successes, Gilead Sciences, Inc. has set its fiscal year 2026 guidance at a negative EPS range, indicating potential challenges ahead that could affect profitability.
  • Equities analysts forecast a negative EPS of -0.78 for the current fiscal year, which may raise concerns about the company's short-term financial health.
  • Some analysts have downgraded their ratings on Gilead Sciences, Inc., reflecting a cautious outlook that could influence investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$180.07 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$158.04 (+8.8% Upside)
Volume
2.29 million shares
Average Volume
7.07 million shares
Today's Range
$143.76
$146.82
50-Day Range
$123.76
$147.60
52-Week Range
$108.46
$157.29
Dividend Yield
2.36%
Pfizer stock logo

13. Pfizer NYSE:PFE

$28.08 -0.16 (-0.57%)
As of 01:58 PM Eastern

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $25, which is relatively stable compared to its twelve-month high of $28.75, indicating potential for growth.
  • Pfizer Inc. reported a quarterly earnings per share (EPS) of $0.77, exceeding analysts' expectations, which reflects strong financial performance and effective management.
  • The company has a solid revenue stream, with a reported $15.03 billion for the latest quarter, surpassing estimates and showing a year-over-year growth of 2.6%.

Cons of Pfizer

  • The high dividend payout ratio of 226.32% raises concerns about sustainability, as it indicates that the company is paying out more in dividends than it earns.
  • Recent analyst downgrades, including a reduction in price targets by several firms, suggest a cautious outlook on the stock's future performance.
  • With a beta of 0.34, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$160.05 billion
P/E Ratio
36.95
Consensus Rating
Hold
Consensus Price Target
$28.28 (+0.7% Upside)
Volume
16.88 million shares
Average Volume
42.10 million shares
Today's Range
$27.65
$28.16
50-Day Range
$23.64
$28.25
52-Week Range
$23.58
$28.75
Dividend Yield
6.31%
Danaher stock logo

14. Danaher NYSE:DHR

$218.68 +7.18 (+3.39%)
As of 01:59 PM Eastern

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The company recently reported earnings per share (EPS) of $1.94, surpassing analysts' expectations, indicating strong financial performance.
  • Danaher Co. has shown a revenue increase of 5.5% compared to the same quarter last year, reflecting growth in its business operations.
  • With a current stock price around $195, it presents a potential buying opportunity given the average target price of approximately $228.91 set by analysts.

Cons of Danaher

  • Several analysts have recently lowered their price targets for Danaher Co., indicating a potential decrease in expected future performance.
  • The company has a return on equity of 11.04%, which, while positive, may be lower compared to industry peers, suggesting less efficiency in generating profits from equity.
  • Despite recent growth, the competitive landscape in the life sciences and diagnostics sectors is intense, which could impact future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.73 billion
P/E Ratio
38.84
Consensus Rating
Moderate Buy
Consensus Price Target
$228.91 (+4.7% Upside)
Volume
3.38 million shares
Average Volume
4.56 million shares
Today's Range
$208.21
$220.67
50-Day Range
$177.74
$211.92
52-Week Range
$160.93
$242.80
Dividend Yield
0.80%
Vertex Pharmaceuticals stock logo

15. Vertex Pharmaceuticals NASDAQ:VRTX

$540.66 -11.40 (-2.06%)
As of 01:57 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $505.75, reflecting strong market interest and potential for growth.
  • Vertex Pharmaceuticals Incorporated reported a revenue increase of 12.5% compared to the same quarter last year, indicating robust business performance.
  • The company has a high net margin of 35.00%, suggesting efficient operations and profitability.

Cons of Vertex Pharmaceuticals

  • The company recently missed analysts' earnings estimates by a small margin, which may raise concerns about future performance.
  • Insider selling activity has been noted, with executives selling shares, which could signal a lack of confidence in the stock's future performance.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 29.44, which may indicate that it is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$137.22 billion
P/E Ratio
31.47
Consensus Rating
Moderate Buy
Consensus Price Target
$563.50 (+4.2% Upside)
Volume
326,153 shares
Average Volume
1.45 million shares
Today's Range
$539.76
$548.99
50-Day Range
$444.92
$552.06
52-Week Range
$374.17
$553.69
Dividend Yield
N/A
Bristol Myers Squibb stock logo

16. Bristol Myers Squibb NYSE:BMY

$66.37 -1.24 (-1.83%)
As of 01:58 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company has received accelerated FDA approval for ZENBEXUS, its first CELMoD therapy, which is expected to enhance its position in the blood-cancer market.
  • Recent earnings projections indicate a strong outlook, with analysts predicting earnings per share of approximately 6.96 for the current fiscal year, suggesting solid financial performance.
  • Bristol-Myers Squibb has expanded its pipeline with a Phase 1 study of golcadomide for kidney disease, indicating potential for long-term growth beyond its oncology products.

Cons of Bristol Myers Squibb

  • A federal appeals court has revived a significant lawsuit alleging that the company delayed drug approvals, which could lead to substantial financial liabilities and legal uncertainties.
  • Rumors of a potential merger with AstraZeneca have created investor concern due to the strategic and execution risks associated with such a large transaction.
  • Despite recent positive developments, the company faces ongoing competition in the oncology space, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$135.57 billion
P/E Ratio
14.62
Consensus Rating
Moderate Buy
Consensus Price Target
$66.06 (-0.5% Downside)
Volume
4.95 million shares
Average Volume
12.25 million shares
Today's Range
$66.08
$67.54
50-Day Range
$54.10
$67.59
52-Week Range
$42.52
$68.64
Dividend Yield
3.82%
Intuitive Surgical stock logo

17. Intuitive Surgical NASDAQ:ISRG

$377.19 -20.53 (-5.16%)
As of 01:58 PM Eastern

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Intuitive Surgical, Inc. has demonstrated strong revenue growth, with a recent quarterly revenue increase of over 18% compared to the previous year, indicating robust demand for its products.
  • The company is a leader in robotic-assisted surgical systems, particularly known for its latest da Vinci surgical systems, which enhance precision and control in minimally invasive surgeries.
  • Analysts have a consensus rating of "Moderate Buy" for Intuitive Surgical, Inc., suggesting positive sentiment among investment professionals regarding the stock's future performance.

Cons of Intuitive Surgical

  • Recent price target reductions by several analysts, including a drop from $573 to $454, may indicate concerns about the stock's near-term performance and market conditions.
  • Despite strong revenue growth, the company faces increasing competition in the medical technology sector, which could impact its market share and profitability.
  • Intuitive Surgical, Inc. has a relatively high valuation compared to its peers, which may pose risks if the company fails to meet growth expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.25 billion
P/E Ratio
43.21
Consensus Rating
Moderate Buy
Consensus Price Target
$508.68 (+34.9% Upside)
Volume
1.96 million shares
Average Volume
2.46 million shares
Today's Range
$375.76
$398.99
50-Day Range
$332.02
$432.83
52-Week Range
$328.57
$603.88
Dividend Yield
N/A
Stryker stock logo

18. Stryker NYSE:SYK

$333.14 -6.84 (-2.01%)
As of 01:59 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company has set a strong FY 2026 guidance with expected earnings per share (EPS) between 14.950 and 15.100, indicating solid financial performance.
  • Recent analyst ratings show a positive outlook, with multiple firms assigning "buy" ratings and target prices ranging from $358.00 to $410.00, suggesting potential for stock appreciation.
  • The current stock price is around $370, which is considered attractive given the company's growth prospects and market position.

Cons of Stryker

  • Recent insider selling, including significant transactions by key executives, may raise concerns about the company's short-term outlook and management's confidence.
  • The stock has experienced fluctuations, and while analysts are optimistic, market volatility could impact short-term performance.
  • With a dividend yield of 1.0%, the income generated may not be sufficient for income-focused investors compared to other investment opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$127.78 billion
P/E Ratio
34.52
Consensus Rating
Moderate Buy
Consensus Price Target
$386.28 (+16.0% Upside)
Volume
715,161 shares
Average Volume
2.36 million shares
Today's Range
$331.78
$342.35
50-Day Range
$301.24
$352.35
52-Week Range
$281.00
$396.86
Dividend Yield
1.06%
CVS Health stock logo

19. CVS Health NYSE:CVS

$93.94 +0.29 (+0.31%)
As of 01:59 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong earnings, with earnings per share (EPS) significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase, suggesting growth and resilience in its business model.
  • CVS Health Co. has set a positive EPS guidance for FY 2026, which could signal continued profitability and growth potential for investors.

Cons of CVS Health

  • The company's net margin is relatively low at 1.18%, which may raise concerns about profitability and operational efficiency.
  • CVS Health Co. has a payout ratio of 70.37%, indicating that a significant portion of its earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Despite recent revenue growth, the competitive landscape in the healthcare sector is intense, which could impact future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$120.15 billion
P/E Ratio
24.85
Consensus Rating
Moderate Buy
Consensus Price Target
$107.17 (+14.1% Upside)
Volume
2.25 million shares
Average Volume
8.41 million shares
Today's Range
$93.21
$94.26
50-Day Range
$93.41
$110.40
52-Week Range
$69.51
$110.68
Dividend Yield
2.80%
Medtronic stock logo

20. Medtronic NYSE:MDT

$92.82 -1.31 (-1.39%)
As of 01:59 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently reported a quarterly revenue of approximately $9.81 billion, exceeding analysts' expectations, indicating strong market performance and demand for its products.
  • The company has a solid return on equity of about 14.51%, reflecting effective management and profitability, which can be attractive to investors looking for efficient capital use.
  • Medtronic plc has increased its quarterly dividend to $0.72, up from $0.71, showcasing its commitment to returning value to shareholders. This translates to an annualized dividend yield of around 3.2%, which can provide a steady income stream for investors.

Cons of Medtronic

  • Despite recent revenue growth, Medtronic plc's earnings per share have shown a decline compared to the same quarter last year, which could raise concerns about its future profitability.
  • The company's payout ratio is currently at 77.21%, indicating that a significant portion of its earnings is being distributed as dividends. This could limit the funds available for reinvestment in growth opportunities.
  • Medtronic plc operates in a highly competitive medical technology market, which may pose risks to its market share and pricing power, especially with the rapid advancement of technology and innovation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.81 billion
P/E Ratio
24.88
Consensus Rating
Moderate Buy
Consensus Price Target
$98.83 (+6.5% Upside)
Volume
2.42 million shares
Average Volume
8.88 million shares
Today's Range
$92.54
$94.53
50-Day Range
$78.04
$94.13
52-Week Range
$73.31
$106.33
Dividend Yield
3.13%
Sanofi stock logo

21. Sanofi NASDAQ:SNY

$45.27 -0.56 (-1.22%)
As of 01:58 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $43, which is significantly lower than its 12-month high, indicating potential for growth.
  • Sanofi has a strong market capitalization of approximately $104.44 billion, suggesting stability and a solid position in the pharmaceutical industry.
  • The company operates across multiple therapeutic areas, including oncology and immunology, which diversifies its revenue streams and reduces risk.

Cons of Sanofi

  • The stock has experienced volatility, with a 12-month low of $40.89, which may concern investors looking for stability.
  • Sanofi's current ratio is below 1, indicating potential liquidity issues, which could affect its ability to meet short-term obligations.
  • The pharmaceutical industry is highly competitive, and Sanofi faces challenges from generic drugs and other market entrants that could impact its market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$109.75 billion
P/E Ratio
23.70
Consensus Rating
Hold
Consensus Price Target
$49.50 (+9.3% Upside)
Volume
1.68 million shares
Average Volume
3.56 million shares
Today's Range
$45.06
$45.74
50-Day Range
$41.33
$45.83
52-Week Range
$40.89
$52.68
Dividend Yield
3.92%
GSK stock logo

22. GSK NYSE:GSK

$52.27 -0.61 (-1.15%)
As of 01:59 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $108, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has a strong market capitalization of approximately $108.73 billion, indicating a solid position in the market and potential for growth.
  • The company has a dividend yield of about 3.3%, providing a steady income stream for investors, which is attractive in a low-interest-rate environment.

Cons of GSK

  • The company has a relatively high price-to-earnings (PE) ratio of 13.97, which may suggest that the stock is overvalued compared to its earnings.
  • GSK plc's price-to-earnings-growth (PEG) ratio of 3.27 indicates that the stock may not be growing fast enough to justify its current valuation, which could deter growth-focused investors.
  • Recent changes in institutional holdings show mixed signals, with some hedge funds increasing their stakes while others are cautious, indicating uncertainty in market sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$105.73 billion
P/E Ratio
16.34
Consensus Rating
Hold
Consensus Price Target
$53.00 (+1.4% Upside)
Volume
2.60 million shares
Average Volume
4.59 million shares
Today's Range
$51.91
$52.63
50-Day Range
$49.54
$53.78
52-Week Range
$38.63
$61.69
Dividend Yield
3.47%
McKesson stock logo

23. McKesson NYSE:MCK

$848.44 -5.27 (-0.62%)
As of 01:59 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. recently reported earnings per share (EPS) of $9.93, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company has shown a revenue increase of 7.7% compared to the same quarter last year, suggesting a positive trend in sales and market demand.
  • McKesson Co. has increased its quarterly dividend to $0.94 per share, reflecting a commitment to returning value to shareholders and indicating financial stability.

Cons of McKesson

  • McKesson Co. has a negative return on equity of 253.21%, which may raise concerns about the company's ability to generate profit from shareholders' equity.
  • The net margin of 1.12% is relatively low, indicating that the company retains a small portion of revenue as profit, which could limit growth potential.
  • Despite recent positive developments, the stock price has shown volatility, which may pose risks for investors looking for stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$98.92 billion
P/E Ratio
22.70
Consensus Rating
Moderate Buy
Consensus Price Target
$973.44 (+14.7% Upside)
Volume
257,682 shares
Average Volume
947,913 shares
Today's Range
$845.36
$858.68
50-Day Range
$745.12
$901.66
52-Week Range
$673.38
$999.00
Dividend Yield
0.38%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$405.43 -1.62 (-0.40%)
As of 01:58 PM Eastern

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $387, which is significantly lower than its one-year high, indicating potential for price appreciation.
  • HCA Healthcare, Inc. reported a strong quarterly earnings per share (EPS) of $7.59, exceeding expectations, which reflects robust financial performance.
  • The company has shown a year-over-year revenue increase of 8.7%, suggesting growth in its operations and market demand for its services.

Cons of HCA Healthcare

  • HCA Healthcare, Inc. has a negative return on equity of 244.79%, which may raise concerns about the company's ability to generate profit from shareholders' equity.
  • The stock has a beta of 1.12, indicating that it is more volatile than the market, which could lead to higher risk for investors.
  • Despite recent revenue growth, the company has a net margin of 8.77%, which may suggest challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$87.78 billion
P/E Ratio
13.57
Consensus Rating
Moderate Buy
Consensus Price Target
$465.59 (+14.8% Upside)
Volume
479,151 shares
Average Volume
1.34 million shares
Today's Range
$403.35
$411.14
50-Day Range
$364.47
$423.06
52-Week Range
$353.99
$556.52
Dividend Yield
0.76%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$396.82 -1.63 (-0.41%)
As of 01:59 PM Eastern

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$86.06 billion
P/E Ratio
17.64
Consensus Rating
Moderate Buy
Consensus Price Target
$440.90 (+11.1% Upside)
Volume
229,843 shares
Average Volume
1.71 million shares
Today's Range
$393.81
$399.59
50-Day Range
$372.20
$430.21
52-Week Range
$274.84
$436.24
Dividend Yield
1.73%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$835.12 -5.72 (-0.68%)
As of 01:57 PM Eastern

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which reflects a strong performance in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. reported impressive quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $82.98 billion, showcasing its stability and growth potential in the biotechnology industry.

Cons of Regeneron Pharmaceuticals

  • The stock has shown volatility, with a 52-week high of $821.11 and a low of $541.00, indicating potential risks associated with price fluctuations.
  • Despite strong earnings, the company's price-to-earnings ratio is around 19.92, which may suggest that the stock is overvalued compared to its earnings growth potential.
  • The dividend yield is relatively low at 0.5%, which may not attract income-focused investors looking for higher returns from dividends.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.98 billion
P/E Ratio
20.64
Consensus Rating
Moderate Buy
Consensus Price Target
$801.70 (-4.0% Downside)
Volume
222,847 shares
Average Volume
848,347 shares
Today's Range
$830.17
$840.82
50-Day Range
$607.93
$840.84
52-Week Range
$541.00
$844.92
Dividend Yield
0.46%
Cigna Group stock logo

27. Cigna Group NYSE:CI

$275.77 -1.68 (-0.61%)
As of 01:58 PM Eastern

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group has a strong earnings forecast, with analysts predicting an earnings per share (EPS) of approximately 30.51 for the current fiscal year, indicating solid financial performance.
  • The company recently declared a quarterly dividend of $1.56, which translates to an annualized dividend of $6.24, providing a yield of around 2.2%. This can be attractive for income-focused investors.
  • Fifteen research analysts have rated The Cigna Group with a Buy rating, reflecting strong market confidence in the company's growth potential.

Cons of Cigna Group

  • Some analysts have downgraded their ratings on The Cigna Group, with price targets being lowered, which may indicate concerns about the company's future performance.
  • The stock has experienced fluctuations, and while the current price is stable, market volatility could pose risks for investors looking for consistent returns.
  • With a significant portion of its business tied to government programs like Medicare and Medicaid, changes in healthcare regulations could adversely affect The Cigna Group's profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.87 billion
P/E Ratio
11.41
Consensus Rating
Moderate Buy
Consensus Price Target
$339.45 (+23.1% Upside)
Volume
380,750 shares
Average Volume
1.69 million shares
Today's Range
$275.12
$278.80
50-Day Range
$270.53
$304.60
52-Week Range
$239.51
$315.47
Dividend Yield
2.27%
Boston Scientific stock logo

28. Boston Scientific NYSE:BSX

$50.00 -2.01 (-3.86%)
As of 01:58 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company recently reported earnings per share of $0.86, surpassing analyst expectations, indicating strong financial performance.
  • Boston Scientific Co. has a robust market capitalization of approximately $73 billion, suggesting a stable and significant presence in the medical device industry.
  • With a recent stock price around $45, the company is seen as potentially undervalued, especially with a share repurchase plan of $5 billion approved by the board, which often signals confidence in the company's future.

Cons of Boston Scientific

  • Despite recent growth, the stock has seen a significant decline from its 1-year high of $109.50, which may raise concerns about its long-term stability.
  • The company has a quick ratio of 0.74, which suggests potential liquidity issues, as it indicates that the company may not have enough short-term assets to cover its short-term liabilities.
  • Recent analyst reports have lowered price targets for the stock, with some estimates dropping to as low as $56, which could indicate a bearish sentiment among market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.46 billion
P/E Ratio
20.24
Consensus Rating
Moderate Buy
Consensus Price Target
$71.62 (+43.2% Upside)
Volume
11.84 million shares
Average Volume
18.24 million shares
Today's Range
$49.77
$51.80
50-Day Range
$42.64
$52.02
52-Week Range
$42.20
$109.50
Dividend Yield
N/A
argenex stock logo

29. argenex NASDAQ:ARGX

$1,033.78 +0.92 (+0.09%)
As of 01:57 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company recently reported earnings per share of $7.32, significantly exceeding analyst expectations, indicating strong financial performance.
  • With a net margin of over 32%, argenx SE demonstrates effective cost management and profitability, which can be attractive to investors looking for financially healthy companies.
  • The current stock price is around $1,025, reflecting positive market sentiment and potential for growth as analysts have set a consensus price target of approximately $1,056.89.

Cons of argenex

  • Despite strong earnings, the biotechnology sector can be highly volatile, and any setbacks in clinical trials or regulatory approvals could negatively impact stock performance.
  • Analysts predict earnings per share for the current year to be around $28.05, which may indicate a slowdown in growth compared to previous periods.
  • The company faces significant competition in the biotechnology space, which could affect its market share and pricing power for its products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.67 billion
P/E Ratio
39.70
Consensus Rating
Moderate Buy
Consensus Price Target
$1,118.28 (+8.2% Upside)
Volume
150,077 shares
Average Volume
348,179 shares
Today's Range
$1,018.98
$1,039.07
50-Day Range
$830.79
$1,032.86
52-Week Range
$658.60
$1,039.07
Dividend Yield
N/A
Cencora stock logo

30. Cencora NYSE:COR

$317.86 +0.76 (+0.24%)
As of 01:59 PM Eastern

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The company has demonstrated strong financial performance with a return on equity exceeding 125%, indicating effective management and profitability relative to shareholder equity.
  • Cencora, Inc. recently announced a quarterly dividend of $0.60, which translates to an annualized yield of approximately 0.7%. This consistent dividend payment can provide a steady income stream for investors.
  • Recent revenue growth of over 5% year-over-year showcases the company's ability to expand its market presence and increase sales, which is a positive indicator for future performance.

Cons of Cencora

  • The net margin is relatively low at around 0.79%, which may indicate challenges in controlling costs or pricing power in a competitive market.
  • Despite revenue growth, the company reported earnings per share of $4.00, which is lower than the previous year's $4.42, suggesting potential profitability concerns.
  • Analysts have mixed expectations for future earnings, with projections for the current fiscal year hovering around 17.84, which may not meet investor expectations for growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.66 billion
P/E Ratio
23.62
Consensus Rating
Moderate Buy
Consensus Price Target
$370.85 (+16.7% Upside)
Volume
528,882 shares
Average Volume
1.54 million shares
Today's Range
$312.61
$318.23
50-Day Range
$271.14
$333.21
52-Week Range
$244.82
$377.54
Dividend Yield
0.76%
Takeda Pharmaceutical stock logo

31. Takeda Pharmaceutical NYSE:TAK

$18.17 -0.17 (-0.93%)
As of 01:58 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The company reported a solid earnings per share of $0.56 in its latest quarterly results, indicating strong profitability and effective management.
  • With a return on equity of 11.20%, Takeda Pharmaceutical Company Limited demonstrates efficient use of shareholders' equity to generate profits, which is a positive sign for potential investors.
  • Recent revenue figures show that the company generated approximately $6.90 billion in the last quarter, reflecting robust business performance and market demand for its products.

Cons of Takeda Pharmaceutical

  • The company has a net margin of 4.31%, which may indicate challenges in maintaining profitability compared to competitors in the biopharmaceutical industry.
  • Recent modifications in institutional holdings show mixed sentiment, with some hedge funds reducing their stakes, which could signal a lack of confidence among large investors.
  • Despite recent revenue growth, the overall market for biopharmaceuticals can be volatile, and Takeda Pharmaceutical Company Limited may face challenges from regulatory changes or competitive pressures.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.22 billion
P/E Ratio
53.44
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
1.21 million shares
Average Volume
3.17 million shares
Today's Range
$18.15
$18.34
50-Day Range
$15.41
$18.37
52-Week Range
$12.99
$18.90
Dividend Yield
2.67%
Cardinal Health stock logo

32. Cardinal Health NYSE:CAH

$230.81 -4.04 (-1.72%)
As of 01:58 PM Eastern

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The company has shown a revenue increase of 5.8% compared to the same quarter last year, indicating growth potential in its operations.
  • Cardinal Health, Inc. has set its FY 2027 guidance at a range of 12.400-12.600 EPS, suggesting a positive outlook for earnings per share.
  • Analysts predict an earnings per share of 12.55 for the current year, which reflects confidence in the company's profitability.

Cons of Cardinal Health

  • The company has a negative return on equity of 98.53%, which may raise concerns about its ability to generate profit from shareholders' equity.
  • Cardinal Health, Inc. reported a net margin of only 0.67%, indicating that its profitability is relatively low compared to its revenue.
  • Despite revenue growth, the firm did not meet analyst estimates for revenue in the latest quarter, which could signal operational challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.68 billion
P/E Ratio
31.92
Consensus Rating
Moderate Buy
Consensus Price Target
$266.56 (+15.5% Upside)
Volume
523,498 shares
Average Volume
2.03 million shares
Today's Range
$230.61
$235.00
50-Day Range
$221.09
$240.08
52-Week Range
$145.87
$258.30
Dividend Yield
0.88%
Moderna stock logo

33. Moderna NASDAQ:MRNA

$132.70 -41.68 (-23.90%)
As of 01:58 PM Eastern

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • Moderna, Inc. reported a second-quarter earnings per share of -$1.97, which was better than the consensus estimate, indicating improved financial performance.
  • The company achieved revenue of approximately $145 million for the quarter, surpassing expectations and showing a year-over-year growth of about 2.1%.
  • Moderna, Inc. has plans for up to 10% revenue growth in 2026, which could enhance future profitability and attract investors looking for growth opportunities.

Cons of Moderna

  • Moderna, Inc. has a negative return on equity of 28.30%, indicating that the company is not generating profit from its equity, which could be a red flag for investors.
  • The company reported a negative net margin of 141.43%, suggesting that it is currently spending significantly more than it earns, raising concerns about its financial health.
  • COVID-19 vaccine sales have been weaker than expected, leading to missed revenue forecasts and highlighting potential challenges in demand for its core products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.98 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$66.25 (-50.1% Downside)
Volume
52.43 million shares
Average Volume
10.19 million shares
Today's Range
$128.61
$155.00
50-Day Range
$49.64
$174.38
52-Week Range
$22.28
$176.66
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

34. Becton, Dickinson and Company NYSE:BDX

$188.46 +0.86 (+0.46%)
As of 01:58 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company has demonstrated a solid quarterly revenue growth of 5.2% year-over-year, indicating a positive trend in its financial performance.
  • Becton, Dickinson and Company has set its fiscal year 2026 earnings per share (EPS) guidance between 12.520 and 12.720, suggesting confidence in future profitability.
  • The current stock price is around $146, which may present a buying opportunity for investors looking for growth in the medical technology sector.

Cons of Becton, Dickinson and Company

  • The company's dividend payout ratio is 106.33%, which means it is paying out more in dividends than it is earning, raising concerns about sustainability.
  • Insider ownership is relatively low at 0.40%, which may suggest a lack of alignment between management and shareholder interests.
  • Recent insider sales, including significant transactions by the CEO and EVP, could signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.93 billion
P/E Ratio
56.77
Consensus Rating
Hold
Consensus Price Target
$185.67 (-1.5% Downside)
Volume
873,132 shares
Average Volume
2.65 million shares
Today's Range
$185.36
$190.01
50-Day Range
$140.37
$187.82
52-Week Range
$127.59
$190.01
Dividend Yield
2.32%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$90.04 -2.24 (-2.43%)
As of 01:59 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported earnings per share of $0.78 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Edwards Lifesciences Co. has shown a year-over-year revenue increase of 13.6%, suggesting a robust demand for its products and services in the medical technology sector.
  • With a return on equity of approximately 15.68%, the company demonstrates effective management of shareholder equity, which can lead to higher returns for investors.

Cons of Edwards Lifesciences

  • Despite positive earnings, the stock has seen fluctuations, which may indicate volatility and risk for investors looking for stable returns.
  • Some analysts have downgraded their ratings, suggesting that there may be concerns about the company's future performance or market conditions.
  • High institutional ownership at 79.46% could lead to less price stability, as large investors may sell off shares quickly in response to market changes.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.85 billion
P/E Ratio
51.75
Consensus Rating
Moderate Buy
Consensus Price Target
$100.27 (+11.4% Upside)
Volume
994,051 shares
Average Volume
4.77 million shares
Today's Range
$89.97
$92.27
50-Day Range
$82.67
$95.17
52-Week Range
$72.30
$96.29
Dividend Yield
N/A
Natera stock logo

36. Natera NASDAQ:NTRA

$330.38 +5.31 (+1.63%)
As of 01:58 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$47.62 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$319.38 (-3.3% Downside)
Volume
846,215 shares
Average Volume
1.36 million shares
Today's Range
$320.00
$333.56
50-Day Range
$212.07
$325.07
52-Week Range
$157.43
$333.56
Dividend Yield
N/A
Humana stock logo

37. Humana NYSE:HUM

$381.55 +3.53 (+0.93%)
As of 01:57 PM Eastern

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $382, reflecting a strong performance in the health insurance sector.
  • Humana Inc. reported a significant year-over-year revenue increase of over 26%, indicating robust growth and demand for its services.
  • The company has consistently beaten earnings expectations, with recent earnings per share surpassing analyst estimates, showcasing effective management and operational efficiency.

Cons of Humana

  • The stock has a relatively high PE ratio of 36.15, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite strong revenue growth, the net margin of 0.88% suggests that profitability may be under pressure, which could affect future earnings.
  • Analysts have mixed ratings on the stock, with some suggesting caution, which may indicate uncertainty about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.82 billion
P/E Ratio
36.10
Consensus Rating
Hold
Consensus Price Target
$395.22 (+3.6% Upside)
Volume
644,957 shares
Average Volume
1.75 million shares
Today's Range
$374.29
$387.79
50-Day Range
$359.99
$409.92
52-Week Range
$163.11
$428.88
Dividend Yield
0.93%
Revolution Medicines stock logo

38. Revolution Medicines NASDAQ:RVMD

$210.62 -4.04 (-1.88%)
As of 01:58 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$45.14 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$166.33 (-21.0% Downside)
Volume
671,031 shares
Average Volume
3.04 million shares
Today's Range
$208.02
$213.74
50-Day Range
$149.23
$216.00
52-Week Range
$35.42
$220.34
Dividend Yield
N/A
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$157.24 +1.83 (+1.18%)
As of 01:59 PM Eastern

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The company recently reported earnings per share (EPS) of $1.49 for the last quarter, exceeding expectations, which indicates strong financial performance and effective management.
  • Agilent Technologies, Inc. has set its fiscal year 2026 guidance at an EPS range of 6.000-6.100, suggesting confidence in continued growth and profitability.
  • The current stock price is around $156, reflecting a stable investment opportunity in a company with a solid market position in scientific instrumentation and services.

Cons of Agilent Technologies

  • Despite recent growth, the stock has faced price adjustments, with some analysts lowering their price targets, which may indicate potential volatility in the stock price.
  • The company operates in a highly competitive market, which could impact its market share and profitability in the long term.
  • Analysts have mixed ratings on the stock, with some downgrading it from "buy" to "hold," suggesting uncertainty about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.41 billion
P/E Ratio
31.57
Consensus Rating
Moderate Buy
Consensus Price Target
$160.24 (+1.9% Upside)
Volume
1.49 million shares
Average Volume
2.20 million shares
Today's Range
$152.12
$159.94
50-Day Range
$124.59
$155.40
52-Week Range
$108.35
$160.27
Dividend Yield
0.69%
Medline stock logo

40. Medline NASDAQ:MDLN

$32.90 -1.01 (-2.98%)
As of 01:58 PM Eastern

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

Market Capitalization
$43.25 billion
P/E Ratio
41.65
Consensus Rating
Moderate Buy
Consensus Price Target
$47.42 (+44.1% Upside)
Volume
3.43 million shares
Average Volume
7.31 million shares
Today's Range
$32.76
$34.19
50-Day Range
$33.81
$43.19
52-Week Range
$32.76
$50.88
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

41. Teva Pharmaceutical Industries NYSE:TEVA

$36.86 -0.61 (-1.63%)
As of 01:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$42.95 billion
P/E Ratio
61.43
Consensus Rating
Moderate Buy
Consensus Price Target
$42.22 (+14.5% Upside)
Volume
1.84 million shares
Average Volume
7.12 million shares
Today's Range
$36.83
$37.35
50-Day Range
$30.19
$37.50
52-Week Range
$17.77
$37.83
Dividend Yield
N/A
IDEXX Laboratories stock logo

42. IDEXX Laboratories NASDAQ:IDXX

$545.13 -17.07 (-3.04%)
As of 01:58 PM Eastern

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $720, which reflects a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. reported a significant increase in quarterly revenue, showcasing a year-over-year growth of nearly 10%, indicating robust demand for its diagnostic products and services.
  • The company has a high return on equity, suggesting effective management and a strong ability to generate profits from shareholders' investments.

Cons of IDEXX Laboratories

  • The company's price-to-earnings (P/E) ratio is relatively high, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • IDEXX Laboratories, Inc. has a quick ratio below 1, indicating that it may face challenges in meeting its short-term liabilities with its most liquid assets.
  • Despite recent growth, the company's debt-to-equity ratio is low, which could limit its ability to leverage debt for expansion or investment opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.95 billion
P/E Ratio
38.34
Consensus Rating
Moderate Buy
Consensus Price Target
$747.00 (+37.0% Upside)
Volume
220,140 shares
Average Volume
583,978 shares
Today's Range
$544.00
$563.13
50-Day Range
$526.44
$595.76
52-Week Range
$518.55
$769.98
Dividend Yield
N/A
IQVIA stock logo

43. IQVIA NYSE:IQV

$258.90 +9.62 (+3.86%)
As of 01:59 PM Eastern

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The company has demonstrated strong financial performance, with quarterly revenue increasing by 8.7% year-over-year, indicating robust growth potential.
  • IQVIA Holdings Inc. has authorized a significant share repurchase program worth $2.00 billion, which suggests that the company's leadership believes its stock is undervalued, potentially enhancing shareholder value.
  • Analysts have a positive outlook on the company, with a consensus rating of "Moderate Buy" and a target price around $241.88, indicating expected appreciation in stock value.

Cons of IQVIA

  • Despite the positive growth, the stock price may face volatility, as indicated by varying target prices from analysts, with some estimates as low as $200.00.
  • There is a risk associated with the company's reliance on institutional investors, as significant sell-offs by these entities could negatively impact stock performance.
  • While the company has shown revenue growth, the projected EPS for the current year is lower than the ambitious long-term guidance, which may raise concerns about short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.61 billion
P/E Ratio
32.12
Consensus Rating
Moderate Buy
Consensus Price Target
$241.88 (-6.6% Downside)
Volume
946,472 shares
Average Volume
1.76 million shares
Today's Range
$246.87
$260.30
50-Day Range
$167.83
$249.62
52-Week Range
$154.50
$260.30
Dividend Yield
N/A
BeOne Medicines stock logo

44. BeOne Medicines NASDAQ:ONC

$373.31 -3.55 (-0.94%)
As of 01:58 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$40.99 billion
P/E Ratio
65.72
Consensus Rating
Buy
Consensus Price Target
$402.14 (+7.7% Upside)
Volume
95,402 shares
Average Volume
292,676 shares
Today's Range
$369.80
$376.00
50-Day Range
$260.27
$376.86
52-Week Range
$253.95
$385.22
Dividend Yield
N/A
Veeva Systems stock logo

45. Veeva Systems NYSE:VEEV

$251.27 +0.27 (+0.11%)
As of 01:58 PM Eastern

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. reported earnings per share of $2.24 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company achieved a revenue of approximately $882.95 million, surpassing estimates, showcasing its ability to generate significant income and expand its market presence.
  • With a return on equity of 13.72%, Veeva Systems Inc. demonstrates effective management of shareholder equity, which is a positive indicator for investors looking for efficient capital use.

Cons of Veeva Systems

  • Despite strong earnings, the stock has seen price target reductions from various analysts, which may indicate concerns about future growth or market conditions.
  • The company operates in a highly competitive sector, which could impact its market share and profitability if competitors introduce superior products or services.
  • Veeva Systems Inc. has a relatively high net margin of 28.37%, which, while positive, may also suggest limited room for cost reductions or pricing flexibility in a competitive landscape.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.82 billion
P/E Ratio
44.79
Consensus Rating
Moderate Buy
Consensus Price Target
$255.58 (+1.7% Upside)
Volume
548,570 shares
Average Volume
2.48 million shares
Today's Range
$246.00
$253.49
50-Day Range
$153.20
$253.17
52-Week Range
$148.05
$310.50
Dividend Yield
N/A
Waters stock logo

46. Waters NYSE:WAT

$411.85 -3.99 (-0.96%)
As of 01:59 PM Eastern

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$40.46 billion
P/E Ratio
102.71
Consensus Rating
Moderate Buy
Consensus Price Target
$420.35 (+2.1% Upside)
Volume
543,154 shares
Average Volume
1.01 million shares
Today's Range
$403.43
$421.74
50-Day Range
$355.10
$416.45
52-Week Range
$282.77
$421.74
Dividend Yield
N/A
Alcon stock logo

47. Alcon NYSE:ALC

$73.45 -0.81 (-1.09%)
As of 01:58 PM Eastern

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $79.18, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a consistent average daily trading volume, indicating active investor interest and liquidity in the stock.
  • Recent short interest data suggests a relatively low short percentage of float, which may indicate investor confidence in the company's future performance.

Cons of Alcon

  • The company has a relatively high number of shares shorted, which could indicate that some investors are betting against the stock.
  • There has been a slight increase in the month-to-month change percentage of shares shorted, suggesting growing skepticism among some market participants.
  • Alcon Inc. has reported zero institutional ownership, which may raise concerns about the company's appeal to larger, more stable investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.33 billion
P/E Ratio
56.07
Consensus Rating
Moderate Buy
Consensus Price Target
$84.63 (+15.2% Upside)
Volume
726,053 shares
Average Volume
1.91 million shares
Today's Range
$73.41
$74.68
50-Day Range
$64.05
$75.25
52-Week Range
$61.83
$87.64
Dividend Yield
N/A
Royalty Pharma stock logo

48. Royalty Pharma NASDAQ:RPRX

$60.94 -0.79 (-1.28%)
As of 01:58 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $56, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Royalty Pharma plc has a strong return on equity of over 30%, indicating effective management and profitability, which can attract investors seeking solid financial performance.
  • The company recently reported earnings that exceeded expectations, showcasing its ability to generate revenue and manage costs effectively.

Cons of Royalty Pharma

  • The company has a relatively high price-to-earnings ratio of 40.41, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Royalty Pharma plc's revenue for the latest quarter fell short of analysts' expectations, indicating potential challenges in meeting growth targets.
  • The firm has a debt-to-equity ratio of 0.88, which, while manageable, suggests that the company is somewhat reliant on debt financing, posing risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.04 billion
P/E Ratio
42.03
Consensus Rating
Buy
Consensus Price Target
$60.86 (-0.1% Downside)
Volume
1.59 million shares
Average Volume
3.51 million shares
Today's Range
$60.80
$62.13
50-Day Range
$52.96
$61.73
52-Week Range
$34.08
$62.13
Dividend Yield
1.57%
DexCom stock logo

49. DexCom NASDAQ:DXCM

$89.92 +0.04 (+0.04%)
As of 01:58 PM Eastern

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The company has demonstrated strong financial performance with a net margin of over 20%, indicating effective cost management and profitability.
  • DexCom, Inc. has a high return on equity of nearly 36%, suggesting that it is efficient in generating profits from its equity investments.
  • Recent quarterly revenue growth of over 13% year-over-year reflects increasing demand for its continuous glucose monitoring systems, which could lead to sustained future growth.

Cons of DexCom

  • Despite strong performance, the stock has received mixed ratings, with one analyst assigning a "Sell" rating, which may indicate potential risks in the market.
  • Recent downgrades from some analysts could signal concerns about future growth or market conditions affecting the company.
  • High institutional ownership at nearly 98% may limit price appreciation potential, as large investors may dominate trading activity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.93 billion
P/E Ratio
35.54
Consensus Rating
Moderate Buy
Consensus Price Target
$88.71 (-1.3% Downside)
Volume
3.51 million shares
Average Volume
5.29 million shares
Today's Range
$89.28
$91.39
50-Day Range
$67.35
$91.48
52-Week Range
$54.11
$91.96
Dividend Yield
N/A
GE HealthCare Technologies stock logo

50. GE HealthCare Technologies NASDAQ:GEHC

$74.83 +0.21 (+0.28%)
As of 01:58 PM Eastern

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $64, which is significantly lower than its 1-year high, indicating potential for growth.
  • The company reported a strong quarterly earnings per share of $1.13, surpassing analysts' expectations, which reflects solid financial performance.
  • GE HealthCare Technologies Inc. has shown a year-over-year revenue increase of 5.8%, suggesting a positive growth trajectory.

Cons of GE HealthCare Technologies

  • The price-to-earnings (P/E) ratio of 16.46 may suggest that the stock is overvalued compared to its earnings, which could deter value investors.
  • The dividend yield is relatively low at 0.2%, which may not be attractive for income-focused investors.
  • The company has a beta of 0.69, indicating lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.80 billion
P/E Ratio
17.16
Consensus Rating
Hold
Consensus Price Target
$77.73 (+3.9% Upside)
Volume
884,169 shares
Average Volume
4.45 million shares
Today's Range
$74.10
$75.65
50-Day Range
$60.58
$74.62
52-Week Range
$58.75
$89.77
Dividend Yield
0.19%